Figure 8. Cisplatin/LPS-primed DCs impaired T cell proliferation in vivo.

A., B., C. One day prior to injection with DCs (LPS/cisplatin-primed DC or LPS-primed DC), Ly5.2⁺ B6/J mice were injected with Ly5.1⁺ OT-I and OT-II T cells. At 5 and 7 days after DC injection, the frequencies of OVA-specific donor CD4⁺ and CD8⁺ T cells in PBMCs A., B. and spleen cells C. were determined by flow cytometry. A. The gating strategy used to detect Ly5.1⁺CD44⁺CD4⁺ T cell and Ly5.1⁺CD44⁺CD8⁺ T cell populations present in the PBMCs at 5 days after injection with DCs. Doublets were excluded based on forward scatter area (FSC-A) vs. forward scatter height (FSC-H), and dead cells were excluded by gating out cells that stained positive with LIVE/DEAD viability dye. Lymphocytes were then gated based on their characteristic pattern of FSC, and SSC was excluded. Activated T cells (determined by the increase of CD44 expression) gated to show Ly5.1⁺CD44⁺CD4⁺ T cell and Ly5.1⁺CD44⁺CD8⁺ T cell populations within the collected PBMCs and spleen cells. B. Ly5.1⁺CD44⁺ T cell frequency was analyzed in the PBMCs at 5 and 7 days after injection with DCs. C. Ly5.1⁺CD44⁺ T cell frequency was analyzed in the spleen cells at 7 days after injection with DCs. The data are expressed as the means ± SD of 4 mice in each group. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the group injected with LPS-primed DCs. LPS: group injected with the LPS-primed DCs (○); LPS+CP: group injected with the LPS/cisplatin-primed DCs (•).